Cementless fixation for total knee arthroplasty (TKA) has gained traction with the advent of newer fixation technologies. This study assessed (1) healthcare utilization (length of stay (LOS), nonhome discharge, 90-day readmission, and 1-year reoperation); (2) 1-year mortality; and (3) 1-year joint-specific and global health-related patient-reported outcome measures (PROMs) among patients who received cementless versus cemented TKA. Patients who underwent cementless and cemented TKA at a single institution (July 2015-August 2018) were prospectively enrolled. A total of 424 cementless and 5,274 cemented TKAs were included. The cementless cohort was propensity score-matched to a group cemented TKAs (1:3-cementless: n =424; cemented: n =1,272). Within the matched cohorts, 76.9% ( n =326) cementless and 75.9% ( n =966) cementless TKAs completed 1-year PROMs. Healthcare utilization measures, mortality and the median 1-year change in knee injury and osteoarthritis outcome score (KOOS)-pain, KOOS-physical function short form (PS), KOOS-knee related quality of life (KRQOL), Veteran Rand (VR)-12 mental composite (MCS), and physical composite (PCS) scores were compared. The minimal clinically important difference (MCID) for PROMs was calculated. Cementless TKA exhibited similar rates of median LOS ( p =0.109), nonhome discharge disposition ( p =0.056), all-cause 90-day readmission ( p =0.226), 1-year reoperation ( p =0.597), and 1-year mortality ( p =0.861) when compared with cemented TKA. There was no significant difference in the median 1-year improvement in KOOS-pain ( p =0.370), KOOS-PS ( p =0.417), KOOS-KRQOL ( p =0.101), VR-12-PCS ( p =0.269), and VR-12-MCS ( p =0.191) between the cementless and cemented TKA cohorts. Rates of attaining MCID were similar in both cohorts for assessed PROMs ( p >0.05, each) except KOOS-KRQOL (cementless: n =313 (96.0%) vs. cemented: n =895 [92.7%]; p =0.036). Cementless TKA provides similar healthcare-utilization, mortality, and 1-year PROM improvement versus cemented TKA. Cementless fixation in TKA may provide value through higher MCID improvement in quality of life. Future episode-of-care cost-analyses and longer-term survivorship investigations are warranted.